Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 and extended cash runway.
Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ahead of expected updates from an upcoming AI conference in Dubai.
TipRanks on MSN
Recursion Pharmaceuticals rises 17.9%
Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17. Published first on TheFly – the ultimate source for real-time, market-moving ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback